Form 4: TriSalus Life Sciences CFO James Emmett Young Reports Transactions
SEC Form 4
James Emmett Young, CFO of TriSalus Life Sciences, reports acquisition of shares and stock options.
Summary
- James Emmett Young, the Chief Financial Officer of TriSalus Life Sciences, filed a Form 4 detailing changes in beneficial ownership.
- On January 27, 2025, Young acquired 12,500 shares of common stock as a grant of restricted stock units (RSU) at $0.
- He also purchased 24,000 shares of common stock at a weighted average price of $5.4, with individual transactions ranging from $5.11 to $5.54.
- Additionally, Young was granted an employee stock option to purchase 75,000 shares of common stock at an exercise price of $5.3, expiring on January 26, 2035.
- The RSU Award vests in four equal annual installments commencing on January 1, 2025, contingent upon continued service.
- One-fourth of the shares subject to the option shall vest on the one-year anniversary of the vesting commencement date of January 1, 2025, and 1/36th of the remaining shares shall vest each month thereafter, subject to continuous service.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. While the acquisitions could be seen as a positive signal, the filing itself is neutral in tone.
Positives
- The acquisition of shares and stock options by the CFO could be interpreted as a sign of confidence in the company's future prospects.
Future Outlook
The vesting schedules for the RSU Award and stock options are contingent upon the Reporting Person's continued service with the Issuer.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Stock option grants and RSU awards are common forms of executive compensation in the life sciences industry, used to align management's interests with those of shareholders.
- The vesting schedules and exercise prices are generally in line with industry norms for companies of similar size and stage of development.
Stakeholder Impact
- The transactions reported in the Form 4 may influence investor sentiment regarding TriSalus Life Sciences.
- The vesting of stock options and RSUs incentivizes the CFO to remain with the company and contribute to its success, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Vesting commencement date for RSU Award and employee stock option. |
| 01/26/2035 | Expiration date for the employee stock option. |
| 01/27/2025 | Date of transaction for stock acquisition and option grant. |
| 01/29/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.